Overview

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Status:
Completed
Trial end date:
2020-10-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
Phase:
Phase 3
Details
Lead Sponsor:
Alnylam Pharmaceuticals